Navigation Links
I-Therapeutix, Inc. Closes $15 Million Financing
Date:6/19/2009

WALTHAM, Mass., June 19 /PRNewswire/ -- I-Therapeutix announced today that it has closed a $15 million dollar Series C financing. The round was led by Polaris Venture Partners in Waltham, MA, with continued participation by existing investors, Versant Ventures and SV Life Sciences.

The proceeds will be used to commercialize I-ZIP(R) Ocular Bandage in the United States and to develop sustained drug delivery products for treatment of ophthalmic diseases and ocular infections.

"We are excited about working with I-Therapeutix to meet significant medical needs in ophthalmology. The company offers a combination of an experienced team with a successful track record, outstanding technology and product opportunities and a compelling business model," said Alan Crane, General Partner at Polaris Venture Partners, who will join the company's Board of Directors.

"In a financing environment that has been challenging for MedTech companies, we welcome the new vote of confidence by Polaris Venture Partners. We look forward to working with our investors to continue building a solid ophthalmic company," commented I-Therapeutix President and CEO, Amar Sawhney.

About I-Therapeutix, Inc:

I-Therapeutix, Inc. is a privately held company based in Waltham, MA focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology. I-Therapeutix is also developing sustained ocular drug delivery vehicles utilizing its proprietary hydrogel polymer technology. The company was founded in November, 2006. The I-ZIP Ocular Bandage has already gained CE Mark approval and is undergoing pivotal clinical investigation in the United States.

About Polaris Venture Partners:

Polaris Venture Partners is a partnership of experienced investors, operating executives and entrepreneurs. The firm's mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. Polaris invests in businesses across a number of markets including life sciences, digital media, technology, consumer, and enertech. The firm has over $3 billion under management, more than 20 investment professionals, and current investments in more than 115 companies. Polaris-backed successes in life sciences include Adnexus (sold to Bristol-Myers Squibb), Advanced Inhalation Research (sold to Alkermes), Alnylam Pharmaceuticals (ALNY), Glycofi (sold to Merck), Momenta Pharmaceuticals (MNTA), and Transform Pharmaceuticals (sold to Johnson & Johnson). Current and former portfolio companies in technology, digital media and consumer include: Akamai Technologies, Allaire, Art.com, Athletes' Performance, HealthCentral Network, JibJab, LogMeIn, Powersoft, Quantcast, Solidworks, TechTarget and WordPress.


'/>"/>
SOURCE I-Therapeutix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HEI, Inc. Closes on Sale of RFID Division Assets
2. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
3. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
4. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
5. MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor
6. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
7. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
8. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
9. BCP Veterinary Pharmacy Helps Cure Diabetic Cats with BCP PZI(R), the Closest Match to Feline Insulin Available
10. Danaher Closes Subsequent Offering Period for Tektronix; Acquires Over 90% of TEK Shares
11. MM2 Group Closes $1.1 Million Sale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... ... “Just What Happened in the Garden of Eden”: retells the stories of three Bible figures ... of published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... three. At six, they moved to Dayton, Ohio, where Penny graduated high school. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology: